Vir Biotechnology Prices $150M Public Offering
Analysis based on 11 articles · First reported Feb 24, 2026 · Last updated Feb 26, 2026
The market is impacted by Vir Biotechnology's public offering as it provides capital for the company's operations, potentially influencing its stock price and future developments in the biotechnology sector. The involvement of major financial institutions like Goldman Sachs and Barclays also signals market confidence in the offering.
Vir Biotechnology, a clinical-stage biopharmaceutical company, announced the pricing of its underwritten public offering of 17,647,058 shares of common stock at $8.50 per share. This offering is expected to generate gross proceeds of $150 million for Vir Biotechnology, before deducting underwriting discounts and commissions. The company has also granted the underwriters, including Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays Capital Inc., a 30-day option to purchase an additional 2,647,058 shares. The offering is expected to close on February 27, 2026, subject to customary closing conditions. The shares are being offered pursuant to a shelf registration statement filed with the United States===United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard